Morgan Stanley Issues Positive Forecast for Phibro Animal Health (NASDAQ:PAHC) Stock Price

Phibro Animal Health (NASDAQ:PAHC) had its price target boosted by equities researchers at Morgan Stanley from $20.00 to $25.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 11.66% from the company’s current price.

Other analysts have also issued research reports about the stock. Barclays raised their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. StockNews.com lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th. JPMorgan Chase & Co. started coverage on Phibro Animal Health in a report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price objective on the stock. Finally, Bank of America upped their target price on Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research note on Friday, August 30th. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.50.

Phibro Animal Health Stock Performance

Shares of PAHC stock traded down $0.25 on Tuesday, hitting $22.39. The company had a trading volume of 37,850 shares, compared to its average volume of 157,057. The firm has a market cap of $906.86 million, a P/E ratio of 52.19, a price-to-earnings-growth ratio of 0.58 and a beta of 0.51. Phibro Animal Health has a twelve month low of $10.03 and a twelve month high of $25.98. The company has a 50-day moving average price of $23.64 and a 200-day moving average price of $20.62. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81.

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds have recently modified their holdings of the company. CWM LLC increased its holdings in shares of Phibro Animal Health by 89.8% during the 2nd quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after buying an additional 1,035 shares during the last quarter. nVerses Capital LLC acquired a new stake in Phibro Animal Health during the third quarter worth $70,000. Quantbot Technologies LP purchased a new stake in Phibro Animal Health in the third quarter valued at $70,000. Summit Securities Group LLC acquired a new position in shares of Phibro Animal Health in the 2nd quarter valued at $83,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Phibro Animal Health by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock worth $88,000 after purchasing an additional 1,522 shares during the period. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.